about
How Chemotherapy Increases the Risk of Systemic Candidiasis in Cancer Patients: Current Paradigm and Future DirectionsNew insights on the development of fungal vaccines: from immunity to recent challengesStudies of Immune Responses in Candida vaginitisMitigating amphibian chytridiomycoses in nature.Calnexin induces expansion of antigen-specific CD4(+) T cells that confer immunity to fungal ascomycetes via conserved epitopes.Inflammatory monocytes orchestrate innate antifungal immunity in the lung.Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis.Secretory Aspartyl Proteinases Cause Vaginitis and Can Mediate Vaginitis Caused by Candida albicans in Mice.Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).Coccidioidomycosis causing osteomyelitis of the hand in an immunocompetent patient.Vaccines in the treatment of invasive candidiasis.New approaches in the development of a vaccine for mucosal candidiasis: progress and challengesVulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013)Progress Toward a Human Vaccine Against CoccidioidomycosisHybrid phage displaying SLAQVKYTSASSI induces protection against Candida albicans challenge in BALB/c miceAntibody-mediated immunity against tuberculosis: implications for vaccine developmentInnate immune cell response upon Candida albicans infectionImmune modulators as adjuncts for the prevention and treatment of invasive fungal infections.Breaking the mould - novel diagnostic and therapeutic strategies for invasive pulmonary aspergillosis in the immune deficient patient.Mitigation of human-pathogenic fungi that exhibit resistance to medical agents: can clinical antifungal stewardship help?Candida antigens and immune responses: implications for a vaccine.Immunological basis of anti-Candida vaccines focused on synthetically prepared cell wall mannan-derived manno-oligomers.Immunological Outcomes of Antibody Binding to Glycans Shared between Microorganisms and Mammals.Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).Future Research Priorities in Fungal Resistance.Vaccination with Phage-Displayed Antigenic Epitope.Th1-Inducing Agents in Prophylaxis and Therapy for Paracoccidioidomycosis.Identification of Fungal T Cell Epitopes by Mass Spectrometry-Based Proteomics.Immunization with Pneumocystis Cross-Reactive Antigen 1 (Pca1) Protects Mice against Pneumocystis Pneumonia and Generates Antibody to Pneumocystis jirovecii.6-O-Branched Oligo-β-glucan-Based Antifungal Glycoconjugate Vaccines.A Convergent Synthesis of 6-O-Branched β-Glucan Oligosaccharides.Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells.An unappreciated role for neutrophil-DC hybrids in immunity to invasive fungal infections.Mycoses and Antifungals: reviewing the basis of a current problem that still is a biotechnological target for marine products
P2860
Q26771113-DC5048FC-8E91-44A6-B69A-6598319B2217Q26776056-2851C319-6C17-4321-AD8A-C90C6B96C305Q26782272-F2C7C6EA-5CE7-4F8F-BB2B-91403597DC81Q30239050-B838B8A3-821A-487D-AC2D-172282C6130BQ34468247-3D612178-954A-4972-91E0-689A682D7664Q35105630-FF2F151C-09D5-45D6-B0BF-5108422BCD33Q35164284-319941ED-934E-4051-892E-B780999B8373Q35650359-3B52BDC6-8906-44C2-AE37-E6194D6D527DQ35672258-33710E87-03D0-4B7D-8B3B-BE5D20C516D8Q36001723-E3367ADD-42EC-45A9-B76B-F07F091DD4ABQ36147010-97A055CF-795D-4A16-8099-2B00C1BA84F8Q36158337-60261116-A1E5-4ED0-8A60-41E1C91B4C02Q36743194-B66C5F31-FEA5-4C90-8381-E9F991FFF794Q36749818-89925926-A6EA-40A9-822F-E8C844CDACA3Q36977827-835A1DA4-1826-4441-B20C-1C6F327E85CCQ37137882-2C6CF9F5-F7C4-4C09-9D58-B786446D8CEDQ37262877-F9C1BB53-9E96-4913-8A31-CA2A1FFFE950Q38067451-EC38BE56-F546-4B31-A74F-FC4FDC17D12DQ38201109-8F39E193-829D-41E4-B440-9C6ABDAA60C7Q38206867-19B256E0-E8B5-44C2-95DB-88F2D4FB62F0Q38222636-51808C3E-FBCE-4BD8-8DAB-3965EFE56778Q38243016-168B74C3-0A4F-436A-BBCF-36E2004271F8Q39013747-7F5E48C6-7058-4420-BE0F-3DDF7CC500D1Q39035805-D038C303-D6A1-4926-AB5F-3E99E8F95A27Q40045680-FF47ECE2-FE6D-41A7-960C-D8AE3E4494A7Q40183763-F67CD25D-FA70-4F8B-B0B7-B1DE3084B8D0Q40183782-889030D9-6F0A-4425-97D6-F61D94F8F519Q40183809-F8067479-A789-4F94-894C-BADB1E0A1B83Q40392438-AD3D6204-66E1-4462-A2F8-F0F3661EAB02Q40541300-11A58919-3BDA-4810-B9CC-49EAC89F4B9DQ42424566-E771E35E-97C1-4DAF-8D84-7BEE5AF65733Q47718243-7CA77B4A-4F30-48F0-AF35-E3081F55B89CQ54204338-C0C25834-E444-415D-92C7-6241A5CF480AQ57900034-50B77422-7ABA-4DEF-ACA9-F6812165FD46
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Recent progress in vaccines against fungal diseases
@ast
Recent progress in vaccines against fungal diseases
@en
type
label
Recent progress in vaccines against fungal diseases
@ast
Recent progress in vaccines against fungal diseases
@en
prefLabel
Recent progress in vaccines against fungal diseases
@ast
Recent progress in vaccines against fungal diseases
@en
P2860
P1476
Recent progress in vaccines against fungal diseases
@en
P2093
Antonio Cassone
Arturo Casadevall
P2860
P304
P356
10.1016/J.MIB.2012.04.004
P577
2012-05-06T00:00:00Z